Anthim obiltoxaximab: Phase III data

A double-blind, placebo-controlled, U.S. Phase III trial in 70 healthy adult volunteers showed that repeat doses of 16 mg/kg IV obiltoxaximab on day 14 or day 120 did not increase the number of adverse events reported after the initial dose on day 1. The most common adverse events related to obiltoxaximab reported were infusion-site swelling, infusion-site erythema and infusion-site pain. No serious adverse events related to obiltoxaximab were reported. Elusys plans to submit a BLA to FDA for obiltoxaximab in 1Q15. ...